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Introduction Poor-quality artemisinin-containing 
antimalarials (ACAs), including falsified and substandard 
formulations, pose serious health concerns in malaria 
endemic countries. They can harm patients, contribute 
to the rise in drug resistance and increase the public’s 
mistrust of health systems. Systematic assessment of drug 
quality is needed to gain knowledge on the prevalence of 
the problem, to provide Ministries of Health with evidence 
on which local regulators can take action.
Methods We used three sampling approaches to 
purchase 677 ACAs from 278 outlets on Bioko Island, 
Equatorial Guinea as follows: convenience survey 
using mystery client (n=16 outlets, 31 samples), full 
island-wide survey using mystery client (n=174 outlets, 
368 samples) and randomised survey using an overt 
sampling approach (n=88 outlets, 278 samples). The 
stated active pharmaceutical ingredients (SAPIs) were 
assessed using high-performance liquid chromatography 
and confirmed by mass spectrometry at three 
independent laboratories.
results Content analysis showed 91.0% of ACAs were 
of acceptable quality, 1.6% were substandard and 
7.4% falsified. No degraded medicines were detected. 
The prevalence of medicines without the SAPIs was 
higher for ACAs purchased in the convenience survey 
compared with the estimates obtained using the full 
island-wide survey-mystery client and randomised-overt 
sampling approaches. Comparable results were obtained 
for full island survey-mystery client and randomised 
overt. However, the availability of purchased artesunate 
monotherapies differed substantially according to the 
sampling approach used (convenience, 45.2%; full 
island-wide survey-mystery client, 32.6%; random-overt 
sampling approach, 21.9%). Of concern is that 37.1% 
(n=62) of these were falsified.
conclusion Falsified ACAs were found on Bioko Island, 
with the prevalence ranging between 6.1% and 16.1%, 
depending on the sampling method used. These findings 
underscore the vital need for national authorities to track 
the scale of ineffective medicines that jeopardise treatment 
of life-threatening diseases and value of a representative 
sampling approach to obtain/measure the true prevalence 
of poor-quality medicines.
IntroductIon
Malaria can be treated, provided access to 
good quality, efficacious medicines is avail-
able.1 2 Plasmodium falciparum parasites cause 
the deadliest form of malaria, which in 2015 
led to 212 million malaria cases and resulted 
in 429 000 deaths.3 The WHO recommends 
artemisinin combination therapies (ACTs) as 
first-line treatment,4 adopted in 81 countries 
by the end of 2014 and shown to have greatly 
contributed to the reduction in malaria 
morbidity and mortality.5 Yet poor-quality 
ACTs (falsified/substandard, unregistered 
and degraded) pose an enormous threat to 
patients who are malaria-infected and may 
lead to drug resistance. Protecting the effi-
cacy of ACTs has recently been declared a 
global public health priority by WHO.6
Falsified monotherapies and ACTs have 
been reported in Africa, where there is a 
high burden of potentially fatal falciparum 
malaria.7 In 2011, we reported the case of a 
Spanish traveller whose life was endangered 
after taking artesunate monotherapy blister 
packed tablets, purchased in Bata, main-
land Equatorial Guinea, which were falsi-
fied as they did not contain the stated active 
pharmaceutical ingredient (SAPI), demon-
strating the threat from counterfeit medi-
cines in this region.8 All medicines imported 
into the country (by donors, government or 
private sector) require the authorisation of 
the Ministry of Health (MoH) in alignment 
with the National Treatment Guidelines and 
the National List for permitted medicines. 
While imported medicines have certificates of 
testing from manufacturers, few verifications 
and tests are performed on Bioko Island to 
determine if the imported medicines satisfy 
the MoH required compliance. As a systematic 
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Figure 1 Map of Bioko Island stratified according to the parasite prevalence (A) and the prevalence of Plasmodium falciparum 
(95% CI) in 2–14 year olds on Bioko Island from 2004 to 2013 (B).
assessment of the quality of medicines had never been 
carried out in Equatorial Guinea, we conducted an 
island-wide survey of outlets to estimate the prevalence of 
poor-quality artemisinin-containing antimalarials (ACAs) 
on sale on Bioko Island, Equatorial Guinea.
MetHods
the study area and sample collection
Bioko Island, Equatorial Guinea, is one of the areas with 
the highest level of malaria transmission in the world.9 
Bioko, which is the site of the country’s capital Malabo, 
is the largest of the five islands of Equatorial Guinea with 
an area of 2017 km² and population of about 250 000. 
Malaria transmission occurs year round, with an esti-
mated entomological inoculation rate ranging from 163 
to 840 in 2009,10 which had decreased to 44 at the time of 
our study in 2013 according to the Bioko Island Malaria 
Control Project (BIMCP) reports. The fight against 
malaria in Equatorial Guinea is conducted via two initia-
tives supporting the National Malaria Control Programme 
(NMCP). In 2004, the BIMCP was launched in collabora-
tion with the NMCP to combat the high malarial burden 
on the island. When the BIMCP began, island-wide prev-
alence of Plasmodium falciparum in children aged 2–14 
years was 45%. Through control measures, including the 
introduction of indoor residual spraying (IRS) and distri-
bution of insecticide-treated nets (ITNs) to all house-
holds on Bioko Island, the prevalence has decreased to 
27.8% in 2013 with a heterogeneous distribution, as seen 
in figure 1A and B.
Key questions
What is already known about this topic?
 ► Early reports indicated that up to 35% of antimalarial medicines, 
purchased using non-representative sampling approaches) from 
21 Sub-Saharan African countries had failed content analysis.
 ► In contrast, recent surveys to determine the quality of artemisinin-
containing antimalarials (ACAs), the current first-line of treatment, 
purchased using systematic sampling approaches in five malaria-
endemic countries in Africa found less than 1% falsified ACAs (only in 
Nigeria), but that substandard ACAs were present in all countries.
What are the new findings?
 ► We used three different sampling approaches (convenience survey 
with mystery client, full island-wide survey with mystery client and 
randomised survey with overt sampling) to purchase 677 ACAs on 
Bioko Island, Equatorial Guinea.
 ► When analysed for content, we found 91.0% ACAs to be of 
acceptable quality (contained the stated active pharmaceutical 
ingredients in the correct concentration), 1.6% to be substandard 
and 7.4% falsified. No degraded medicines were detected.
 ► These findings substantiate previous reports of the presence of 
falsified Coartem in parts of West and Central Africa and provides 
additional evidence on the often overlooked problem of substandard 
medicines—both of which render treatment ineffective.
recommendations for policy
 ► These data underscore the vital need for national authorities to track 
the scale of ineffective medicines that jeopardise treatment of a 
life-threatening disease and the value of using a different sampling 
approach to understand the true prevalence of poor-quality medicines.
 ► The methods used on Bioko Island can be used by Ministries 
of Health to carry out regular surveillance to track the scale of 
substandard medicines in other countries.
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In addition to IRS and ITNs, the BIMCP has supported 
the NMCP in providing the first-line ACAs free of 
charge since 2005. ACAs used in Equatorial Guinea have 
included artesunate plus sulfadoxine-pyrimethamine 
and artesunate plus amodiaquine. The latter was intro-
duced in August 2008 as first-line treatment of uncom-
plicated malaria. However, while free of charge, ACTs are 
available on the island, many people do not choose to get 
medicines at public health centres and complain of side 
effects.11 The 2013 Malaria Indicator Survey revealed that 
only 38.6% of the interviewees who were sick in the past 
week and reported a positive malaria test, received treat-
ment from the public health services, where medicines 
are free, while 55.7% sought their medicines at a private 
pharmacy.
A number of guidelines, including STROBE,12 
MEDQUARG13 and a recently published checklist of 
criteria for designing and reporting of medicine quality 
studies,14 informed the study design and analysis methods 
reported in this manuscript. In May 2013, the BIMCP 
conducted an island-wide census to identify both regis-
tered and unregistered drug providers, listing 278 outlets 
consisting of 180 pharmacies, 53 medicine vendors and 
45 private clinics (see online supplementary table 1). 
Outlets were georeferenced, classified and included in 
the master database. Drug quality surveys were carried 
out at outlets listed in the census in three phases in June 
2013. A team of 16 local surveyors worked in pairs to 
visit the outlets assigned to them by the supervisor, after 
receiving 2 days of training, including a 1-day pilot run to 
pretest the sample collection approaches.
Samples purchased included as many different brands 
and formulations as possible (i.e., blister packed tablets, 
granules, injections, capsules, syrups and suspensions, 
including age-specific dosage packages for the same 
brand). The minimum amount of each sample bought 
was defined as six individual units (i.e., six loose tablets, 
six ampoules for injection, six granule packs) or one 
bottle of the suspension. For blister packed tablets, ‘one 
sample’ was approximately one complete blister pack.
convenience survey using mystery client
During the first phase (9 and 10 June 2013), outlets 
were purposely selected by the study team following 
the convenience survey with mystery client approach as 
recommended by United States Pharmacopeia,15 in an 
attempt to purchase as wide a variety of available medi-
cines as possible. A total of 31 ACAs were purchased by 
4 surveyors from 16 outlets which intentionally included 
providers that were suspected of selling outdated and 
unregistered products.
Full island-wide survey using mystery client approach
Bioko Island is small with relatively few licensed and unli-
censed drug outlets; hence, it was feasible to visit them all. 
In the second phase (11–16 June 2013), all outlets open 
for business were visited by eight teams consisting of two 
surveyors per team, using a mystery client approach to 
purchase ACAs. The surveyors approached the provider 
using one of three predetermined scenarios where they 
feigned that they or a member of their family were sick 
and needed medications or that they needed to send 
antimalarials to relatives in the village. The surveyors 
acted as either a patient, a patient’s friend or relative 
requesting to see all ACAs available before purchasing. 
A total of 174 outlets were visited and found to be open 
and selling ACAs.
randomised survey using overt sampling approach
A simple randomised subset of 88 outlets (50.5%) 
was drawn from a list of 174 eligible outlets (104 were 
excluded because they were either permanently closed 
or not selling antimalarials during the initial survey using 
the mystery clients). This third phase, undertaken by 
four teams of two surveyors each, was completed in 6 
days (17–22 June 2013) and 278 ACAs were purchased. 
The provider was informed of the purpose of the drug 
purchase and their consent sought to participate in 
the study. A structured questionnaire was completed 
on the availability, supply and costs of the ACAs they 
sold. Providers were also questioned about their level of 
training, dispensing practices and storage conditions of 
medications.
sample processing
At the end of each sample purchasing trip, the survey 
teams returned to the BIMCP offices in Malabo and 
completed an information form for every sample 
purchased recording the following information: the 
outlet type, date of purchase, the price paid, brand name, 
formulation, batch number, manufacture and expiry 
date. Each sample was placed in an individual zip-lock 
bag together with data recorded on their corresponding 
information forms and stored securely in an air-condi-
tioned room (≈20oC) pending dispatch to the London 
School of Hygiene and Tropical Medicine (LSHTM), 
London, UK via DHL Express, for further processing.
At LSHTM, digital photographs of packaging and 
contents were taken and sample information (brand 
name, SAPIs, dose form, outlet, district, date of purchase, 
name of stated manufacturer, country of manufacture, 
presence of the Affordable Medicines Facility—malaria, 
green leaf AMFm logo, batch number, date of manufac-
ture, expiry date, number of tablets per blister packed 
and price paid) was checked with the information 
collected in the field and logged in a database using Epi 
Info V.3.5.16 Each tablet was weighed and its dimensions 
recorded prior to laboratory analysis.
Laboratory sAPI content analysis
For quantitative analysis by high-performance liquid 
chromatography with photodiode array (HPLC-PDA) 
detection, each pulverised tablet was combined with the 
appropriate solvent (see online supplementary table 2), 
sonicated and centrifuged. The supernatant, containing 
soluble active ingredients, was then injected into the 
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HPLC column and the amount of SAPIs present in 
the tablet was determined. Other formulations (injec-
tions, granules, capsules, syrups and suspensions) were 
dissolved in methanol prior to HPLC analysis. HPLC 
analysis was conducted using a Dionex Ultimate 3000 
system (Thermofisher, Hemel Hempstead, UK) and 
separation achieved using a GENESIS AQ 4 µm column 
(150×4.6 mm, Grace Materials Technologies, Cranforth, 
UK) or Acclaim 120, C18, 5 µm Analytical (4.6×150 mm) 
from Fisher Scientific, Leicestershire, UK. The mobile 
phase was a gradient of ammonium formate (10 mM, pH 
2.7), and acetonitrile (v/v; 15:85 to 85:15 over 7.0 min) 
at the flow rate of 1.0 mL/min was used to analyse all 
the formulations. Online supplementary table 2 outlines 
information of the solvents, columns, concentration 
injected and wavelengths set on the detector (DAD 3000) 
used to measure the SAPIs as well as the source of the 
reference standards for the HPLC analysis. A duplicate 
sample of the ones analysed at LSHTM from each packet 
were sent to the US Centres for Disease Control and 
Prevention (CDC) Laboratories in Atlanta, Georgia, USA 
for confirmatory HPLC analyses as well as to the Georgia 
Institute of Technology (GT), in Atlanta, Georgia, 
USA for ambient mass spectrometry (MS) analyses to 
verify the ingredients present and identify any unstated 
compounds.17 18 Each laboratory analysed the SAPIs in 
the combinations using different methodologies (HPLC 
columns and eluents). In general, there was very good 
agreement (mean bias was 1.16 with 95% CI ranging 
from 15.4 to 17.8), between the results from the two labo-
ratories where quantitation work was carried out (CDC 
and LSHTM) as shown by the Bland Altman plots (see 
online supplementary figure 1).
classification of samples
The World Health Assembly recently agreed to adopt 
substandard, unregistered and falsified to define medi-
cine quality.19 Where substandard refers to ‘out of specifi-
cation’ medicines, these are authorised medical products 
that fail to meet either their quality standards or their 
specifications or both. ‘Unregistered’ defines any medical 
products that have not undergone evaluation and/or 
approval by the national or regional regulatory authority 
for the market in which they are marketed/distributed 
or used, subject to permitted conditions under national 
or regional regulation and legislation. ‘Falsified’ medical 
products deliberately/fraudulently misrepresent their 
identity, composition or source. Additional classifica-
tions are the degraded formulations that may result from 
exposure of good-quality medicines to light, heat and/or 
humidity. It is important to detect the products of degra-
dation of SAPIs to distinguish degraded medicines from 
those that left the factory as substandard.20
Due to the lack of registration and verification of medi-
cines entering Equatorial Guinea, it was not possible to 
determine if medicines in our study were unregistered or 
out of specification. Therefore, classification of medicines 
was solely based on their measured SAPI content and not 
on registration status. Laboratory results were expressed 
as a percentage of the SAPI on the packaging (% SAPI). 
This was determined for both SAPIs including the arte-
misinin derivative and the associated partner drug, a 
non-artemisinin antimalarial. To accommodate the varia-
tion in HPLC laboratory testing of less than 10 samples of 
each ACA formulation, we adopted the tolerance range 
of 85%–115% for this study.21–23 If the % SAPI of a drug 
was found to be outside of this tolerance band, then a 
second sample from the same packet was analysed and 
the average outcome reported (except suspensions as the 
entire bottle was used in the first analysis). The % SAPI 
was used to classify each sample as one of the following: 
being of acceptable quality (85%–115% for both SAPIs); 
substandard (<85% or >115% of either SAPI). Classifica-
tion of analysed medicines as ‘degraded’ was achieved 
through comparison of HPLC retention times and MS 
patterns of good quality medicines with that obtained 
from artificially degraded samples.20 Degraded samples 
contained products of degradation of either and/
or both SAPIs. Artificial degradation was achieved by 
placing good quality artemether-lumefantrine (Coartem, 
Novartis, China) and artesunate-amodiaquine tablets 
(Winthrop, Maphar Laboratories, Morocco) in an oven 
at 60oC for 21 days.20 Samples were classified as falsified, 
when they were found to not contain the SAPIs, when they 
contained other compounds not listed on the packaging 
and when visible package differences were present after 
comparison with the packaging from acceptable quality 
medicines. Please note that packages from ACAs, where 
the SAPIs were found to comply with the pharmacopoeia 
tolerance limits (acceptable quality products), were used 
for comparison purposes, as authentic packaging could 
not be obtained from the manufacturers who hold the 
patents.
data analysis
Laboratory data were combined with survey and sample 
data (S1 Data base) and analysed using STATA V.12 (Stat-
acorp, College station, Texas, USA). Proportions were 
evaluated using χ² tests, and crude associations between 
poor-quality ACAs and variables collected from the ques-
tionnaire were examined. A univariate logistic model 
assessed associations with poor-quality products and 
factors associated with a p<0.1 on crude analysis were 
included in a multivariate model. The survey command 
(svy) of the software was used to compute clustering at 
the outlet level.
ethics approvals and findings reported to authorities
The study was approved by the LSHTM Ethics Committee 
(Ref: 5804), and ethical approval from Equatorial Guin-
ea’s MoH was secured. This study did not involve patients, 
hence written consent was not required. Verbal consent 
was given by the person in charge of the outlet during the 
randomised-overt survey sampling approach which was 
recorded on the database. Findings were reported to the 
MoH on Bioko Island; manufacturers of medicines found 
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Table 1 Chemical analyses of antimalarial medicines purchased using three approaches (convenience-mystery clients, full 
island-wide survey-mystery clients and randomised-overt sampling) on Bioko Island, Equatorial Guinea; n=677
Outlets (n) Acceptable Quality AD and PD Substandard Degraded Falsified Total
  Convenience survey using mystery client (samples=31; total brands=12; brands per outlet=0.8)
Pharmacies (10) 16 (76.2%) 1 (4.8%) 0 4 (19.0%) 21
Medicine vendors (6) 9 (90.0%) 0 0 1 (10.0%) 10
Private clinics (0)   0 0 0  0 0
All outlets (16) 25 (80.7%)* 1 (3.2%) 0 5 (16.1%)*** 31
  Full island-wide survey using mystery client (samples=368; total brands=60; brands per outlet=0.3)
Pharmacies (108) 236 (91.1%) 2 (0.8%) 0 21 (8.1%) 259
Medicine vendors (33) 50 (92.6%) 0 0 4 (7.4%) 54
Private clinics (33) 52 (94.5%) 0 0 3 (5.5%) 55
All outlets (174) 338 (91.9%)* 2 (0.5%)** 0 28 (7.6%) 368
  Randomised-overt survey(samples=278; total brands=64; brands per outlet=0.7)
Pharmacies (62) 213 (90.2%) 7 (3.0%) 0 16 (6.8%) 236
Medicine vendors (14) 8 (100.0%) 0 0  0 8
Private clinics (12) 32 (94.2%) 1 (2.9%) 0 1 (2.9%) 34
All outlets (88) 253 (91.0%) 8 (2.9%)** 0 17 (6.1%)*** 278
Significant difference between sampling approaches for each quality category was as follows:
*p=0.037: between convenience survey using mystery clients and full island-wide survey using mystery clients for acceptable quality (AD and 
PD) samples.
**p=0.017: between full island-wide survey using mystery clients and randomised-overt survey for substandard samples.
***p=0.040: between convenience survey using mystery clients and randomised-overt survey for falsified samples.
Other comparisons were not significantly different (p>0.050).
Acceptable quality: 85%–115% SAPIs for both AD and PD.
Substandard: <85% or >115% SAPI of either AD or PD or both.
Degraded: <85% SAPI plus products of degradation of either/both AD or PD or both.
Falsified: zero SAPI for both AD and PD and visible differences (mistakes) on the packaging.
ACA, artemisinin-containing antimalarial; AD, artemisinin derivative (always the ACA); PD, partner drug (always the non-ACA); SAPI, stated 
active pharmaceutical ingredient.
to be falsified; Global Fund drug quality section and the 
WHO ( rapidalert@ who. int).
resuLts
Samples of ACAs (n=677) consisting of artemisinin 
monotherapies (AMTs) and ACTs were purchased 
from 278 outlets selling antimalarial medicines, located 
mainly in the capital, Malabo (64.7% pharmacies, 19.1% 
medicine vendors and 16.2% private clinics; see online 
supplementary table 1). SAPI content analyses were 
carried out in three independent laboratories to provide 
robust estimates of the prevalence of acceptable quality, 
substandard, falsified and degraded AMTs and ACTs. 
Overall, the majority (64.7%) of pharmacies and private 
clinics (without inpatient capacity) had at least one ACA 
available at the time of the randomised-overt survey, while 
only about a quarter of the medicine vendors had an ACA 
available (see online supplementary table 1). The medi-
cine vendors included a diverse group of outlets: some of 
them sell various household items, including medicines, 
while others sell only medicines either in a small shop 
or just inside their house, in a clandestine way. Medicine 
vendors and private clinics were more likely than pharma-
cies to have staff with a health-related qualification and/
or recent malaria training (past 12 months); however, 
pharmacies on average stocked almost four times as 
many ACA samples of varying brands than the medicine 
vendors.
Table 1 shows the quality of ACAs purchased using 
the various sampling strategies. The convenience survey 
using mystery client yielded 17 ACTs and 14 AMTs, 
representing 12 different brands, purchased from 16 
outlets. Of these, 80.7% were of acceptable quality 
(containing 85–115 for both SAPIs), 3.2% substandard 
and 16.1% were falsified that did not contain the SAPIs 
but contained unstated compounds that were not listed 
on the packets. The full island-wide survey using mystery 
client yielded 60 brands purchased from 174 outlets (368 
samples; 196 ACTs and 172 AMTs). Among these, 91.9% 
were acceptable quality medicines, 5% substandard and 
7.6% were falsified. The randomised survey using overt 
sampling approach found 132 ACTs and 146 AMTs, 64 
brands purchased from 88 outlets. From these samples, 
91.0% were of acceptable quality, 2.9% substandard and 
6.1% were falsified. No degraded samples were detected 
among any of the medicines purchased on Bioko Island, 
suggesting that the duration and conditions of storage of 
the medicines were adequate.
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Table 2 Quality of artemisinin-containing antimalarials at 76 outlets visited during both the island-wide survey using mystery 
client and the randomised-overt survey on Bioko Island, Equatorial Guinea
Variable
Sampling method
p ValueIsland-wide survey-mystery client Randomised-overt survey
Outlets 76 of 174 (43.7%) 76 of 88 (86.4%)
Samples 170 245
Brands 44 (64.7%) 58 (85.3%) 0.0057*
Authentic 154 (90.6%) 227 (92.7%) 0.45
Substandard 2 (1.2%) 6 (2.4%) 0.35
Degraded 0 0
Falsified 14 (8.2%) 12 (4.9%) 0.17
Total number of brands purchased=68.
*Significant difference.
All samples were analysed using MS to confirm the 
presence or absence of the SAPI and confirmed the 
HPLC results. Compounds present in falsified formula-
tions identified by MS included bis(2-ethylhexyl) adipate, 
dioctyl adipate, chlorzoxazone, ciprofloxacin, 2-mercap-
tobenzothiazole, sildenafil, stearic acid, a disaccharide 
and a polymer of sugar alcohol (see online supplemen-
tary table 3). All but four of these unstated compounds 
were detected among samples collected by at least two of 
the different sampling approaches.
A significantly higher proportion of falsified medicines 
were found in samples purchased using the convenience 
survey compared with the randomised-overt sampling 
(table 1, 16.1% vs 6.1%, p=0.040); Convenience mystery 
client approach also yielded a lower proportion of ACAs 
of acceptable quality than the island-wide survey-mystery 
client approach (80.7% vs 91.9% respectively, p=0.037).
data on medicine quality
Direct comparison of the full island-wide survey using 
mystery client and randomised survey using overt sampling 
approaches showed that, for a subset of 76 outlets that 
were visited during both sampling approaches, a greater 
number of samples and significantly more brands were 
collected using the randomised-overt approach (samples: 
245 and 170: 58 and 44, respectively; table 2). There were 
no significant differences in the proportion of poor-
quality medicines purchased using these two sampling 
methods (p>0.05 in all cases).
In all three sampling approaches, approximately half 
of the medicines purchased were ACTs (345) and the 
other half were AMTs (332), which included mono-
therapy suspensions (7), injections (129), capsule (1) and 
blister packed tablets (195). The availability of artesunate 
monotherapy tablets differed significantly according to 
sampling approach (convenience-mystery client=45.2%; 
full island-wide survey-mystery client=32.6%; randomised-
overt sampling approach=21.9%; table 3) and 23 out 
of 62 blister packed tablets (37.1%) of artesunate were 
found not to contain the SAPI. No AMTs of dihydroarte-
misinin were found among the purchased samples. Half 
of the samples that were found not to contain the SAPIs 
(n=50), purchased during all three sampling approaches 
were stated to be manufactured by WHO prequalified 
companies (table 4).
Packaging examination
We did not succeed in obtaining authentic samples of 
medicines and packaging from manufacturers who hold 
the patents. Hence, detailed investigations of the pack-
aging were conducted between acceptable quality (85%–
115% for both SAPIs) and substandard medicines, (<85% 
of SAPIs) to check for identifiable visible differences, 
including signs of tampering, that is, deliberate change 
of batch number, manufacturing or expiry dates. There 
were no visible differences in the packaging between the 
acceptable quality and substandard medicines as well as 
no obvious indications that they had been manufactured 
by anyone other than the stated manufacturer.
In contrast, packaging associated with samples that were 
found not to contain the SAPIs but contained unstated 
compounds, and therefore classified as falsified, showed 
noticeable differences to packaging of acceptable quality 
medicines. For example, the falsified package for Arte-
sunat (see online supplementary scan 1) had misspell-
ings, a different mosquito, a different hologram and a 
different registration number as reported previously.8 
All of the writing on the acceptable quality packets of 
Vatunate artesunate is in green ink whereas the falsified 
packets are in black ink, the front of the packet is half-
green and half white (see online supplementary scan 2). 
Comparison of packets of Coartem showed that the falsi-
fied product had a 24-month time period between the 
manufacturing and expiry dates whereas the manufac-
turer, Novartis, confirmed that it should be 23 months. 
Additionally, the backs of the blister packed fully covered 
with cardboard circles whereas the acceptable quality 
product has half circles of cardboard (see online supple-
mentary scan 3). Package containing falsified tablets of 
dihydroartemisinin-piperaquine packaged as Duo-co-
tecxin had a stamp stating, ‘donated by P R China’, 
and the colours on the packets are faded while the lot 
Kaur H, et al. BMJ Glob Health 2017;2:e000409. doi:10.1136/bmjgh-2017-000409 7
BMJ Global Health
Ta
b
le
 3
 
D
es
cr
ip
tio
n 
of
 a
ll 
sa
m
p
le
s 
p
ur
ch
as
ed
 u
si
ng
 t
hr
ee
 s
am
p
lin
g 
ap
p
ro
ac
he
s 
(c
on
ve
ni
en
ce
-m
ys
te
ry
 c
lie
nt
, i
sl
an
d
-w
id
e 
su
rv
ey
-m
ys
te
ry
 c
lie
nt
 a
nd
 r
an
d
om
is
ed
-o
ve
rt
 
su
rv
ey
) o
n 
B
io
ko
 Is
la
nd
, E
q
ua
to
ria
l G
ui
ne
a;
 n
=
67
7
Va
ri
ab
le
C
o
nv
en
ie
nc
e-
m
ys
te
ry
 c
lie
nt
Is
la
nd
-w
id
e 
su
rv
ey
-m
ys
te
ry
 c
lie
nt
R
an
d
o
m
is
ed
-o
ve
rt
 s
ur
ve
y
P
ha
rm
M
V
s
P
C
s
To
ta
l
P
ha
rm
M
V
s
P
C
s
To
ta
l
P
ha
rm
M
V
s
P
C
s
To
ta
l
A
rt
em
is
in
in
 c
om
b
in
at
io
n 
th
er
ap
ie
s
A
M
-L
U
M
10
 (9
0.
9%
)
3 
(5
0.
0%
)
0
13
 (7
6.
5%
)
10
4 
(7
3.
8%
)
9 
(8
1.
8%
)
11
 (2
5.
0%
)
12
4 
(6
3.
3%
)
92
 (7
7.
3%
)
2 
(1
00
.0
%
)
9 
(8
1.
8%
)
10
3 
(7
8.
0%
)
A
S
-A
D
Q
1 
(9
.1
%
)
2 
(3
3.
3%
)
0
3 
(1
7.
6%
)
22
 (1
5.
6%
)
2 
(1
8.
2%
)
33
 (7
5.
0%
)
57
 (2
9.
1%
)
15
 (1
2.
6%
)
0
2 
(1
8.
2%
)
17
 (1
2.
9%
)
A
S
-M
E
F
0
0
0
0
1 
(0
.7
%
)
0
0
1 
(0
.5
%
)
0
0
0
0
A
S
-S
U
LF
M
E
X
-P
Y
R
0
1 
(1
6.
7%
)
0
1 
(5
.9
%
)
12
 (8
.5
%
)
0
0
12
 (6
.1
%
)
11
 (9
.2
%
)
0
0
11
 (8
.3
%
)
D
H
A
-P
IP
0
0
0
0
2 
(1
.4
%
)
0
0
2 
(1
.0
%
)
1 
(0
.9
%
)
0
0
1 
(0
.8
%
)
To
ta
l
11
6
0
17
14
1
11
44
19
6
11
9
2
11
13
2
A
ll 
m
on
ot
he
ra
p
ie
s 
(s
us
p
en
si
on
s,
 n
=
7;
 in
je
ct
io
ns
, n
=
12
9;
 c
ap
su
le
s,
 n
=
1 
an
d
 t
ab
le
ts
, n
=
19
5)
A
M
0
0
0
0
30
 (2
5.
4%
)
13
 (3
0.
2%
)
1 
(9
.1
%
)
44
 (2
5.
6%
)
54
 (4
6.
2%
)
2 
(3
3.
3%
)
10
 (4
3.
5%
)
66
 (4
5.
2%
)
A
S
10
 
(1
00
.0
%
)
0
4 
(1
00
.0
%
)
14
 
(1
00
.0
%
)
88
 (7
4.
6%
)
30
 (6
9.
8%
)
10
 (9
0.
9%
)
12
8 
(7
4.
4%
)
63
 (5
3.
8%
)
4 
(6
6.
7%
)
13
 (5
6.
5%
)
80
 (5
4.
8%
)
To
ta
l
10
0
4
14
11
8
43
11
17
2
11
7
6
23
14
6
M
on
ot
he
ra
p
y 
b
lis
te
r 
p
ac
ke
d
 t
ab
le
ts
 (n
=
19
5)
A
S
10
 
(1
00
.0
%
)
0
4 
(1
00
.0
%
)
14
* 
(1
00
.0
%
)
84
 
(1
00
.0
%
)
26
 
(1
00
.0
%
)
10
 
(1
00
.0
%
)
12
0*
* 
(1
00
.0
%
)
50
 
(1
00
.0
%
)
2 
(1
00
.0
%
)
9 
(1
00
.0
%
)
61
*, *
* 
(1
00
.0
%
)
D
os
e 
fo
rm
Ta
b
le
ts
21
 
(1
00
.0
%
)
10
 
(1
00
.0
%
)
0
31
 
(1
00
.0
%
)
21
7 
(8
3.
8%
)
36
 (6
6.
7%
)
52
 (9
4.
6%
)
30
5 
(8
2.
9%
)
14
3 
(6
0.
6%
)
2 
(2
5.
0%
)
13
 (3
8.
2%
)
15
8 
(5
6.
8%
)
C
ap
su
le
s
0
0
0
0
0
0
0
0
1 
(0
.4
%
)
0
0
1 
(0
.4
%
)
S
us
p
en
si
on
s
0
0
0
0
8 
(3
.1
%
)
1 
(1
.9
%
)
2 
(3
.6
%
)
11
 (3
.0
%
)
31
 (1
3.
2%
)
3 
(3
7.
5%
)
7 
(2
0.
6%
)
41
 (1
4.
7%
)
In
je
ct
io
ns
0
0
0
0
34
 (1
3.
1%
)
17
 (3
1.
4)
1 
(1
.8
%
)
52
 (1
4.
1%
)
60
 (2
5.
4%
)
3 
(3
7.
5%
)
14
 (4
1.
2%
)
77
 (2
7.
7%
)
G
ra
nu
le
s/
p
ow
d
er
s
0
0
0
0
0
0
0
0
1 
(0
.4
%
)
0
0
1 
(0
.4
%
)
To
ta
l
21
10
0
31
25
9
54
55
36
8
23
6
8
34
27
8
W
H
O
 p
re
q
ua
lifi
ca
tio
n
N
ot
 W
H
O
 
p
re
q
ua
lifi
ed
9 
(4
2.
9%
)
5 
(5
0.
0%
)
0
14
 (4
5.
2%
)
14
2 
(5
4.
8%
)
32
 (5
9.
3%
)
7 
(1
2.
7%
)
18
1 
(4
9.
2%
)
15
6 
(6
6.
1%
)
6 
(7
5.
0%
)
22
 (6
4.
7%
)
18
4 
(6
6.
2%
)
W
H
O
 p
re
q
ua
lifi
ed
12
 (5
7.
1%
)
5 
(5
0.
0%
)
0
17
 (5
4.
8%
)
11
7 
(4
5.
2%
)
22
 (4
0.
7%
)
48
 (8
7.
3%
)
18
7 
(5
0.
8%
)
80
 (3
3.
9%
)
2 
(2
5.
0%
)
12
 (3
5.
3%
)
94
 (3
3.
8%
)
To
ta
l
21
10
0
31
25
9
54
55
36
8
23
6
8
34
27
8
S
ta
te
d
 r
eg
io
n 
of
 m
an
uf
ac
tu
re
A
fr
ic
a
0
0
0
0
8 
(3
.1
%
)
0
32
 (5
8.
2%
)
40
 (1
0.
9%
)
9 
(3
.8
%
)
0
0
9 
(3
.2
%
)
C
on
tin
ue
d
8 Kaur H, et al. BMJ Glob Health 2017;2:e000409. doi:10.1136/bmjgh-2017-000409
BMJ Global Health
Va
ri
ab
le
C
o
nv
en
ie
nc
e-
m
ys
te
ry
 c
lie
nt
Is
la
nd
-w
id
e 
su
rv
ey
-m
ys
te
ry
 c
lie
nt
R
an
d
o
m
is
ed
-o
ve
rt
 s
ur
ve
y
P
ha
rm
M
V
s
P
C
s
To
ta
l
P
ha
rm
M
V
s
P
C
s
To
ta
l
P
ha
rm
M
V
s
P
C
s
To
ta
l
A
si
a
16
 (7
6.
2%
)
8 
(8
0.
0%
)
0
24
 (7
7.
4%
)
19
3 
(7
4.
5%
)
45
 (8
3.
3%
)
17
 (3
0.
9%
)
25
5 
(6
9.
3%
)
16
3 
(6
9.
1%
)
7 
(7
0.
0%
)
29
 (9
0.
6%
)
19
9 
(7
1.
6%
)
E
ur
op
e
0
1 
(1
0.
0%
)
0
1 
(3
.2
%
)
19
 (7
.3
%
)
1 
(1
.9
%
)
2 
(3
.6
%
)
22
 (6
.0
%
)
28
 (1
1.
9%
)
1 
(1
0.
0%
)
3 
(9
.4
%
)
32
 (1
1.
5%
)
N
or
th
 A
m
er
ic
a
5 
(2
3.
8%
)
1 
(1
0.
0%
)
0
6 
(1
9.
4%
)
35
 (1
3.
5%
)
4 
(7
.4
%
)
4 
(7
.3
%
)
43
 (1
1.
7%
)
22
 (9
.3
%
)
0
0
22
 (7
.9
%
)
N
ot
 s
ta
te
d
0
0
0
0
4 
(1
.6
%
)
4 
(7
.4
%
)
0
8 
(2
.1
%
)
14
 (5
.9
%
)
2 
(2
0.
0%
)
0
16
 (5
.8
%
)
To
ta
l
21
10
0
31
25
9
54
55
36
8
23
6
10
32
27
8
S
ig
ni
fic
an
t 
d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
p
ro
p
or
tio
n 
of
 m
on
ot
he
ra
p
y 
(A
S
) t
ab
le
ts
 p
ur
ch
as
ed
 u
si
ng
 t
he
 t
hr
ee
 s
am
p
lin
g 
ap
p
ro
ac
he
s 
w
as
 a
s 
fo
llo
w
s:
*p
=
0.
00
4:
 b
et
w
ee
n 
co
nv
en
ie
nc
e-
m
ys
te
ry
 c
lie
nt
 (4
5.
2%
) a
nd
 r
an
d
om
is
ed
-o
ve
rt
 s
ur
ve
y 
(2
1.
9%
).
**
p
=
0.
00
3:
 b
et
w
ee
n 
is
la
nd
-w
id
e 
su
rv
ey
-m
ys
te
ry
 c
lie
nt
 (3
2.
6%
) a
nd
 r
an
d
om
is
ed
-o
ve
rt
 s
ur
ve
y 
(2
1.
9%
).
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
co
nv
en
ie
nc
e-
m
ys
te
ry
 c
lie
nt
 a
nd
 is
la
nd
-w
id
e 
su
rv
ey
-m
ys
te
ry
 c
lie
nt
s.
A
D
Q
, a
m
od
ia
q
ui
ne
; A
M
, a
rt
em
et
he
r;
 A
R
T,
 a
rt
em
is
in
in
; A
S
, a
rt
es
un
at
e;
 D
H
A
, d
ih
yd
ro
ar
te
m
is
in
in
; L
U
M
, l
um
ef
an
tr
in
e;
 M
E
F,
 m
efl
oq
ui
ne
; M
V
s,
 m
ed
ic
in
e 
ve
nd
or
s;
 P
C
s,
 p
riv
at
e 
cl
in
ic
s;
 P
ha
rm
, 
p
ha
rm
ac
ie
s;
 P
IP
, p
ip
er
aq
ui
ne
; P
Y
R
, p
yr
im
et
ha
m
in
e;
 S
U
LD
O
X
, s
ul
fa
d
ox
in
e;
 S
U
LF
M
E
X
, s
ul
fa
m
et
ho
xy
p
yr
id
az
in
e.
 
Ta
b
le
 3
 
C
on
tin
ue
d
 
number, manufacturing and expiry date are missing (see 
online supplementary scan 4).
risk factors for substandard, degraded and falsified 
medicines
There was no significant difference in the drug quality 
among the artemether, artesunate and dihydroartemis-
inin formulations nor between samples of medicines 
produced by WHO prequalified manufacturers compared 
with those from manufacturers that are not prequalified 
(table 4). At the time of the laboratory analysis, all but 
five samples were within their expiry dates of which one 
packet of tablets was falsified and the four suspensions 
were substandard. Among pharmacies, a slightly higher 
proportion of the ACAs sampled were of poor quality, 
compared with ACAs purchased from medicine vendors 
or private clinics, though the risk was not significantly 
increased (p=0.14, table 4). In contrast, samples labelled 
with the AMFm logo were more likely to be of poor 
quality than those that were not (p<0.001). In addition, 
poor-quality medicines were associated with stated manu-
facture in North America (p<0.001). These findings are 
likely to be influenced by the large number of falsified 
Coartem samples that were in circulation. Approximately 
50% (26 out of 54) of the Coartem purchased were 
found to be falsified (see online supplementary table 4). 
Five variants of falsified Coartem were identified (batch 
numbers F1901, F2261, F2596 and NOF2153), all alleg-
edly manufactured by Novartis and with the AMFm logo, 
with one exception (F1901), yet containing a range of 
various compounds instead of the SAPIs. In addition to 
the falsified Coartem, 86% (19 of the 22) of the Artesunat 
monotherapy samples purchased were found to be falsi-
fied.
dIscussIon
Poor-quality ACAs are postulated to cause a serious 
direct health risk to consumers and several studies have 
focused on the impact of falsified medicines on public 
health.1 2 7 8 21–23 Recently, additional concern has been 
raised over the possibility that substandard antimalarials 
could lead to drug resistance as a result of underdosing, 
though the association has yet to be proven.24 Identi-
fying the scale of substandard and falsified ACAs in the 
market place in malaria-endemic countries is an essential 
first step to address this impediment in the fight against 
malaria.
Over 90% of samples of ACTs and AMTs (n=677, 142 
brands) purchased from pharmacies, medicine vendors 
and private clinics on Bioko Island were found to be of 
acceptable quality (contained the specified SAPIs). The 
poor-quality medicines consisted of substandard (1.6%) 
and falsified ACAs (7.4%), where the latter contained 
compounds other than the SAPIs. No degraded medicines 
were detected indicating either storage in the absence of 
high heat and humidity and/or a fast turnover of medi-
cines. The reliability of these findings is supported by the 
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Table 4 Risk factors associated with substandard (n=11) and falsified (n=50) ACAs (n=677)
Sample characteristics  
of ACAs
Total number 
of samples
Poor-quality 
samples
Crude ORs
(95% CI)
Likelihood- 
ratio p value
Generic type AM 350 34 (9.7%) 1 0.36
DHA 3 1 (33.3%) 4.6 (0.4 to 52.6)
AS 324 26 (8.0%) 0.8 (0.5 to 1.4)
WHO prequalified/
AQACT
Not prequalified 379 35 (9.2%) 1 0.82
Prequalified 298 26 (8.7%) 0.9 (0.6 to 1.6)
AMFm Non-AMFm medicines 579 36 (6.2%) 1 <0.001
AMFm medicines 98 25 (25.5%) 5.2 (2.9 to 9.1)
Region of stated country 
of manufacture
Asia 471 33 (7.0%) 1 <0.001
North America 71 26 (36.6%) 7.7 (4.2 to 14.0)
Not stated 73 2 (2.7%) 0.4 (0.1 to 1.6)
Expired at time of 
analysis
Not expired 663 56 (8.4%) 1 <0.001
Expired* 14 5 (35.7%) 6.0 (2.1 to 17.0)
Outlet type Pharmacies 519 51 (9.8%) 1 0.14
Medicine vendors 75 5 (6.7%) 0.7 (0.3 to 1.7)
Private clinics 89 5 (5.6%) 0.5 (0.2 to 1.4)
*Of the five expired samples, one was a falsified tablet and four were substandard suspensions.
ACAs, artemisinin-containing antimalarials; AM, artemether; AMFm, Affordable Medicines Facility—malaria; AQACT, acceptable quality-
artemisinin combination therapy; AS, artesunate; DHA, dihydroartemisinin; ORs, odds ratio.
use of standardised sampling procedures to purchase 
the samples followed with analysis at three independent 
laboratories. Laboratory analysis of samples using both 
HPLC-PDA and MS techniques confirmed the absence 
of the SAPIs and the presence of alternative compounds, 
none of which have antimalarial properties.
Packets of artesunate monotherapies were available on 
Bioko, despite these products not being recommended 
by WHO for the treatment of uncomplicated falciparum 
malaria nor included in the NMCP treatment guidelines 
for Equatorial Guinea, as monotherapies are considered 
to be a major contributing factor to the development of 
artemisinin resistance.25 Of additional concern is that 
37.1% of artesunate monotherapy samples analysed were 
falsified, that is, did not contain the SAPI and had notice-
able differences in the packaging from that of acceptable 
quality samples. This is of particular relevance given the 
first reported case of falsified artesunate monotherapy, 
which almost resulted in a fatality, was purchased on the 
Equatorial Guinea mainland.8 Both the absence of one 
or both of the SAPI in an ACT or AMT lead to absence 
of drug efficacy, which can cause dangerous effects/
events. Furthermore, the availability of monotherapies 
can increase the risk of drug resistance.26
Our results are reassuring in that samples labelled with 
the AMFm logo or from WHO prequalified manufac-
turers were less likely to have concerns related to medicine 
quality than those without these accreditations. However, 
there is still a need for vigilance with these products, 
as highlighted by samples of falsified Coartem 20/120 
(batch F2261) bearing the AMFm logo originally and 
allegedly manufactured by Novartis, that were originally 
sold in Angola27 28 and subsequently purchased in Enugu 
metropolis, Nigeria21 and Bioko Island (current study). 
These particular batches of Coartem were also reported 
by Novartis to be found in Cameroon.29 30 Relying solely 
on packaging appearance to detect falsified medicines 
may not be sufficient, and results in this study suggest 
that using devices that have the potential to detect the 
chemical quality of drugs at the point of purchase should 
be used. A low-cost, hand-held near-infrared spectrom-
eter device marketed at currently USD 250 has recently 
been demonstrated to be effective in identifying the 
falsified samples of Coartem across multiple batches 
and manufacturing locations.31 Such low-cost screening 
devices could greatly facilitate the ability of regulatory 
authorities to screen the quality of medicines as well as 
identify suspect products in need of confirmatory phar-
macopoeia methods such as HPLC, regarded as the gold 
standard.
When comparing the estimates obtained using different 
sampling approaches, the prevalence of falsified medi-
cines was higher for ACAs purchased using the conve-
nience survey-mystery client approach compared with 
the island-wide mystery client and random survey-overt 
sampling approaches. These findings are not surprising 
as the outlets chosen in the convenience mystery client 
approach were selected based on local knowledge to 
include outlets known to sell expired medicines, medi-
cines banned in other countries and/or medicines 
without proper labelling, thus increasing the probability 
that they also had falsified antimalarials. A previous study 
in Enugu, Nigeria (n=3024) similarly noted a higher 
proportion of falsified samples were purchased when 
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using a convenience mystery client approach (3.0%) 
versus a full survey using mystery client or random-overt 
sampling approach (1.2% and 0.6%, respectively).21 In 
contrast, in both studies, there was no significant differ-
ence in the quality of the medicines purchased using the 
mystery shopper or overt sampling approach. Together, 
these findings indicate that either sampling strategy 
could be used effectively to determine drug quality in a 
geographical region. However, as each approach has its 
own advantages and disadvantages, the survey objectives 
need to be considered to ensure that the most appro-
priate sampling strategy is chosen.21 For example, overt 
sampling has the advantage of being able to collect addi-
tional information using outlet questionnaires, enabling 
detailed data collection on sources as well as risk factors 
for poor-quality medicines, at minimal added cost. Our 
findings also indicate that it may be easier to collect a 
greater variety of medicines at each outlet using an 
overt sampling approach rather than mystery shopper. 
However, as outlet staff are aware that a survey is taking 
place, there is a risk that they may withhold known poor-
quality medicines from the survey team. While this study 
did not indicate that this sampling bias was present 
based on the percentage of falsified medicines, fewer 
monotherapy treatments, which are not in the country’s 
National Treatment guidelines, were collected during 
the overt sampling. The mystery client approach has 
the advantage of a lower inherent risk of sampling bias 
as outlets are unaware of the survey. However, as shown 
in our study, it is difficult to obtain as many samples 
from each outlet using this approach. In this study, 
both the island-wide survey using mystery client and the 
randomised-overt sampling approaches yielded similar 
results for each classification of drug quality (acceptable, 
substandard and falsified while no degraded samples were 
found) indicating that the selection bias often assumed to 
be the limitation of overt surveys was not a major concern 
in this setting. This would further suggest that in contrast 
to monotherapies which are readily identifiable, vendors 
are not necessarily aware of which medicines may be of 
poor quality. While the packaging of falsified medicines 
in this study had noticeable differences (spelling, logo, 
differences in colour and so on) to those from acceptable 
quality medicines, these differences may not be obvious 
to the untrained eye. Laboratory analysis of samples 
using both HPLC-PDA and MS techniques confirmed 
the absence of the SAPIs and the presence of alternative 
compounds, none of which has antimalarial properties.
Our results from Bioko Island show that Coartem and 
artesunate monotherapy tablets are most likely to be falsi-
fied in this setting. The risk of purchasing a falsified drug 
was greater from a pharmacy than other sources. Yet only 
one-third of the pharmacies in the census were officially 
registered with the MoH, highlighting the challenge to 
be faced in obtaining reliable estimates of drug quality in 
settings where regulation is weak and surveys hampered 
by factors such as lack of sampling frame, rapid turn-
over of outlets, providers fearing regulation and/or 
reprisal, staff safety and anonymity. Nevertheless, in many 
countries, a major share of antimalarial treatments are 
obtained from unregulated providers, and drug quality 
in these outlets needs to be a priority for research. Our 
study shows that carrying out a census of pharmacies in 
the area before conducting a survey, and not just relying 
on a list of registered pharmacies from the MoH, can 
help identify unregistered outlets to be included in the 
sampling frame.
concLusIon
Our data show how a convenience survey using mystery 
client can be useful to identify ‘hot spots’ of poor-quality 
medicines, but that a representative survey based on a 
defined sampling frame, and using either mystery client 
or an overt approach to purchase drugs, is needed to 
accurately quantify and track the scale of ineffective medi-
cines. Our investigation did not find the prevalence of 
poor-quality medicines on Bioko Island to be as alarming 
as reported elsewhere in Sub-Saharan Africa,32–34 but we 
did find ACA medicines that did not contain the SAPIs 
and were in falsified packaging. The findings from Bioko 
Island reinforce those from our previous study in Enugu, 
Nigeria and highlight the need for routine monitoring 
of medicine quality, following a representative sampling 
approach, to ensure that the available treatments for 
life-threatening diseases are not jeopardised.
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